Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The U1 small nuclear ribonucleoprotein (snRNP)–pre-messenger RNA (pre-mRNA) complex is a critical early intermediate in the eukaryotic pre-mRNA splicing process. It is formed by the base-pairing of the U1 small nuclear RNA (snRNA) with the 5' splice site (5'ss) of an intron, a process supported by a core of Sm proteins and U1-specific proteins such as U1-70K, U1-A, and U1-C (UniProt P08621, P09012, P09234). This complex serves as the primary recognition module for the 5'ss, initiating the assembly of the spliceosome and ensuring the precise removal of introns (PubMed 25529373). In diseases such as Spinal Muscular Atrophy (SMA), mutations in the SMN2 gene weaken the U1 snRNP–5'ss interaction, leading to the exclusion of exon 7 and the production of a truncated, unstable protein (PubMed 29335545). Therapeutic intervention focuses on small molecules that act as splicing modifiers, which bind to the U1 snRNP–pre-mRNA interface to stabilize the complex and promote exon inclusion (PubMed 32531193). These drugs, including Risdiplam and Branaplam, represent a novel class of molecular glues that target RNA-protein interactions to correct genetic defects.
Small molecule splicing modifiers act as molecular glues to stabilize the transient interaction between the U1 snRNP and the 5' splice site of specific pre-mRNAs, thereby promoting the inclusion of exons that would otherwise be skipped due to weak splice site recognition.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U1 small nuclear ribonucleoprotein–pre-messenger RNA complex (U1 snRNP–pre-mRNA) (U1 snRNP–pre-mRNA).